Comparative Effectiveness of Pioglitazone and Rosiglitazone in Type 2 Diabetes, Prediabetes,and the Metabolic Syndrome: A Meta-Analysis

Publisher： Bentham Science Publishers

E-ISSN： 1875-6417|3|2|127-140

ISSN： 1573-3998

Source： Current Diabetes Reviews, Vol.3, Iss.2, 2007-05, pp. : 127-140

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Progression rates from HbA1c 6.0–6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis

By Morris D.   Khunti K.   Achana F.   Srinivasan B.   Gray L.   Davies M.   Webb D.  

Diabetologia, Vol. 56, Iss. 7, 2013-07 ,pp. : 1489-1493

Springer Publishing Company

Access to resources Recommend Favorite

Effect of pioglitazone on systemic inflammation is independent of metabolic control and cardiac autonomic function in patients with type 2 diabetes

By Nerla Roberto   Pitocco Dario   Zaccardi Francesco   Scalone Giancarla   Coviello Ilaria   Mollo Roberto   Ghirlanda Giovanni   Lanza Gaetano   Crea Filippo  

Acta Diabetologica, Vol. 47, Iss. 1, 2010-12 ,pp. : 117-122

Springer Publishing Company

Access to resources Recommend Favorite

Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD

By  

Current Cardiology Reviews, Vol. 6, Iss. 2, 2010-05 ,pp. : 112-118

Bentham Science Publishers

Access to resources Recommend Favorite

Spotlight on Rosiglitazone in the Management of Type 2 Diabetes Mellitus

By Wagstaff A.J.   Goa K.L.  

Treatments in Endocrinology, Vol. 1, Iss. 6, 2002-01 ,pp. : 411-414

Adis International

Access to resources Recommend Favorite

Spotlight on Pioglitazone in Type 2 Diabetes Mellitus

By Waugh John   Keating Gillian M.   Plosker Greg L.   Easthope Stephanie   Robinson Dean M.  

Treatments in Endocrinology, Vol. 5, Iss. 3, 2006-01 ,pp. : 189-191

Adis International

Access to resources Recommend Favorite